C-Ray Therapeutics

Executive Summary

C-Ray Therapeutics is a clinical-stage biotechnology company based in Suzhou, China, focused on developing novel antibody-based therapeutics for cancer. Founded in 2018, the company specializes in differentiated monoclonal and bispecific antibodies that modulate the tumor microenvironment and enhance anti-tumor immunity, aiming to overcome resistance to current immunotherapies. With a lean team of 50-200 employees, C-Ray is advancing its pipeline through Phase 1 clinical trials. The company's approach targets key immune checkpoints and stromal components, potentially offering new treatment options for patients who do not respond to existing therapies. While financial details are undisclosed, the private company has progressed from discovery to early clinical development, indicating meaningful internal investment or prior funding. As a China-based biotech, C-Ray benefits from the region's rapid clinical trial enrollment and supportive regulatory environment, though it faces competition from global and local players. The next major milestones involve generating proof-of-concept data from ongoing Phase 1 studies and expanding its pipeline into new indications.

Upcoming Catalysts (preview)

• Q4 2026Interim Phase 1 Data for Lead Bispecific Antibody40% success
• Q1 2027IND Filing for Second-Generation Monoclonal Antibody70% success
• H2 2026Strategic Partnership or Licensing Deal30% success